FDA approves Amgen's T-cell engager for lung cancer, BioMarin announces layoffs, FDA delays Ascendis drug review [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good —  FDA approves Amgen T-cell engager for small cell lung cancer 
The bad — BioMarin announces 170 layoffs 
The ugly — FDA delays review of Ascendis hypoparathyroidism drug